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ABSTRACT
Background Lifestyle interventions focusing on weight
loss remain the cornerstone of non-alcoholic fatty liver
disease (NAFLD) management. Despite this, the weight
losses achieved in research trials are not easily
replicated in the clinic and there is an urgent need for
therapies independent of weight loss. Aerobic exercise is
not well sustained and the effectiveness of the better
tolerated resistance exercise upon liver lipid and
mediators of liver lipid has not been assessed.
Methods Sedentary adults with clinically deﬁned NAFLD
were assigned to 8 weeks of resistance exercise (n¼11)
or continued normal treatment (n¼8).
Results 8 weeks of resistance exercise elicited a 13%
relative reduction in liver lipid (14.069.1 vs 12.269.0;
p<0.05). Lipid oxidation (submaximal RQ Δ
 0.02060.010 vs  0.00460.003; p<0.05), glucose
control ( 12% vs +12% change AUC; p<0.01) and
homeostasis model assessment insulin resistance
(5.965.9 to 4.664.6 vs 4.762.1 to 5.162.5; p<0.05)
were all improved. Resistance exercise had no effect on
body weight, visceral adipose tissue volume, or whole
body fat mass (p>0.05).
Conclusion This is the ﬁrst study to demonstrate that
resistance exercise speciﬁcally improves NAFLD
independent of any change in body weight. These data
demonstrate that resistance exercise may provide
beneﬁt for the management for non-alcoholic fatty liver,
and the long-term impact of this now requires evaluation.
Non-alcoholic fatty liver disease (NAFLD) repre-
sents a spectrum from asymptomatic steatosis to
potentially life-threatening non-alcoholic steatohe-
patitis, with an overall prevalence of NAFLD in
western countries of 20e30%.
1 Patients with
simple steatosis have a relatively benign ‘liver’
prognosis with a 1e2% risk of developing clinical
evidence of cirrhosis over 15e20 years. Patients
with non-alcoholic steatohepatitis and ﬁbrosis can
progress to cirrhosis at a rate of approximately 12%
over 8 years.
2 Once cirrhosis develops, patients are
at a high risk of developing hepatic decompensation
and of dying from a liver-related cause.
To date, weight loss is the only conﬁrmed
therapy for the treatment of NAFLD, and lifestyle
interventions remain the cornerstone of manage-
ment.
1 2 Thiozolidinedione therapy has shown
promise in providing a temporary reduction in liver
fat,
34although progressive weight gain, side effects
and cost have prevented them from being used in
routine care. Lifestyle interventions have been
shown to reduce markers of liver lipid and meta-
bolic control
5e7 in addition to reducing intrahepatic
lipid (IHL).
8e11 However, weight loss is difﬁcult to
achieve and sustain. Physical activity and exercise
in NAFLD management could potentially be
effective in decreasing IHL. Cross-sectional studies
have shown that higher levels of physical activity
are associated with lower levels of IHL.
51 21 3To
date, two studies have reported a beneﬁcial effect of
aerobic exercise regimes upon liver function, inde-
pendent of weight loss.
14 15 However, the use of
aerobic exercise may not be optimal as the high
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Signiﬁcance of this study
What is already known about this subject?
< Lifestyle interventions incorporating weight loss
improve liver fat in NAFLD.
< Weight loss is difﬁcult to achieve in clinical
practice.
< Evidence on the effect of exercise on liver fat is
insufﬁcient, limiting the effective use of exercise
in clinical care.
What are the new ﬁndings?
< Resistance exercise reduces liver fat indepen-
dent of weight loss in people with NAFLD.
< Resistance exercise improves fat oxidation
independent of weight loss in people with
NAFLD.
< Resistance exercise improves glucose control
independent of weight loss in people with
NAFLD.
How might it impact on clinical practice in the
foreseeable future?
< Helping people achieve and sustain a physically
active lifestyle is one of the most pressing
clinical needs for NAFLD management.
< This study demonstrates that resistance exer-
cise holds clinical beneﬁts, independent of
weight loss, and provides an alternative to
aerobic exercise.
< The lower cardiorespiratory demand may also
make resistance exercise more accessible to
patients than aerobic exercise, improving long-
term sustainability.
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Hepatologycardiorespiratory demand is associated with fatigue and
discomfort, and long-term compliance is poor. Population-based
studies
13 suggest that resistance exercise is associated with lower
levels of IHL. Resistance exercise has a lower cardiorespiratory
demand and is associated with similar metabolic beneﬁts. There
have been no previous studies of the direct effect of resistance
exercise upon IHL and metabolism, even though it has clear
advantages in terms of acceptability and sustainability.
16 17
The primary aim of this study was to determine the effect of
resistance exercise without weight loss, on IHL in adults with
NAFLD. The secondary aims were to determine the effect of
resistance exercise on mediators of IHL; glucose tolerance and
insulin sensitivity, fat oxidation, abdominal adiposity and body
composition.
EXPERIMENTAL PROCEDURES
Twenty-eight people with NAFLD were screened for this study.
Seven were excluded after screening (two transpired to be taking
insulin for their diabetes; one was excluded due to an abdominal
hernia; four due to <5% IHL on baseline MRI). Twenty-one
sedentary (#60 min vigorous activity per week) adults with
clinically deﬁned non-advanced NAFLD were therefore randomly
assigned to either exercise (n¼11) or standard care (n¼10). The
study was powered to detect a 2.02% absolute change (Δ)i n
intrahepatic lipid between the treatment and control groups (SD
2.8%, a 5% and b 50%), based on changes reported from an
aerobic exercise study in NAFLD.
14 Non-advanced NAFLD was
deﬁned as greater than 5% IHL and a score of less than  1.445 on
the NAFLD ﬁbrosis scoring system,
18 which indicates a lower
percentage chance of having stage 3/4 ﬁbrosis. General descrip-
tions can be found in table 1. Exclusion criteria included heart or
kidney disease, implanted ferrous metal, pre-existing medical
conditions preventing participation in the exercise programme,
insulin sensitising treatment or dietary change (for people with
type 2 diabetes mellitus, diet and metformin were acceptable for
inclusionifstablefor6 months)andalcoholintakeabove21units
for men or 14 units for women. Subjects would be excluded from
analysis if body weight changed more than 2.5% from baseline
during the study as this could have an independent effect on IHL.
The study protocol was approved by County Durham and Tees
Valley 2 Research Ethics Committee. All participants provided
written informed consent. Following an initial screening visit,
glucose control, lipid oxidation, abdominal lipid depots and liver
lipidweremeasuredatbaselineandafterthe8-weekintervention.
Progressive exercise test/screening visit
At baseline, a medical history, full physical examination and
progressive exercise test were used to screen for undiagnosed
cardiac disease. Resting 12-lead ECG (Custo med GmbH, Otto-
brunn, Germany) and blood pressure (Suntech Tango+, Suntech
Medical Ltd, Oxford, UK) were measured, in a seated position,
to determine normal cardiac function. Peak oxygen consumption
was determined using an electronically braked recumbent cycle
ergometer (Corival Lode BV, Groningen, The Netherlands).
Following a 5 min warm up at 25 W, resistance was increased by
1 W per 8 s until the participant could no longer maintain
a cadence of 60 rpm, chose to stop, or continuing was contra-
indicated. The ECG was used to monitor heart rhythm contin-
uously and blood pressure was measured every 2 min during the
exercise test. Expired gases were collected using a Hans Rudolf
breathing mask and analysed online for oxygen consumption,
carbon dioxide elimination and ventilation (CORTEX Biophysik,
Leipzig, Germany).
Physical activity
Physical activity and energy expenditure were assessed objec-
tively using a validated
19 multisensor array (SenseWear Pro3,
Bodymedia Inc, Pennsylvania, USA) worn on the right upper
arm for 7 days before random assignment and for the ﬁnal
7 days of the intervention. The armband provided estimates of
daily energy expenditure, average metabolic equivalents, seden-
tary time, duration and intensity of physical activity, number of
steps, sleep duration and duration armband worn.
Anthropometry
Body weight and body composition were measured using an
electronic scale and air displacement plethysmography (BodPod,
Life Measurement Inc, California, USA).
20e22 Height was
measured with a stadiometer (SECA 799; SECA, Birmingham,
UK). Waist circumference was measured at the midpoint
between the lower costal margin and the level of the anterior
superior iliac crests. Hip circumference was measured at the level
of the greater trochanter.
Liver and abdominal fat measurement
Magnetic resonance studies were performed using a 3 Tesla
Philips Achieva scanner (Philips Medical Systems, Best, The
Netherlands). Following an 8 h fast, IHL was measured by
localised
1H-MRS (PRESS, TR/TR 3000 ms/35 ms, 33333c m
Table 1 Subject characteristics
Control Exercise Time 3 treatment
interaction (p value) Baseline Post-treatment p Value Baseline Post-treatment p Value
Anthropometry
BMI (kg/m
2) 32.3 (4.8) 32.5 (4.2) 0.42 32.3 (4.9) 32.3 (4.5) 0.89 0.43
Weight (kg) 94.0 (12.0) 94.6 (10.7) 0.37 96.1 (10.9) 96.1 (10.5) 0.99 0.44
Waist circumference (cm) 108 (9) 110 (7) 0.42 107 (11) 109 (12) 0.32 0.55
Hip circumference (cm) 110 (6) 115 (9) 0.06 110 (9) 111 (9) 0.85 0.13
Waist to hip ratio 0.99 (0.05) 0.96 (0.06) 0.16 0.97 (0.06) 0.98 (0.06) 0.21 0.15
VO2peak (ml/kg per min) 18.5 (5.2) ee 21.8 (3.8) ee e
Metabolic
ALT (U/l) 61.6 (41.4) 61.4 (44.0) 0.92 59.6 (38.6) 59.6 (39.0) 0.99 0.98
Total cholesterol (mmol/l) 4.5 (1.1) 4.6 (0.9) 0.47 5.0 (1.8) 5.0 (1.7) 0.67 0.46
Triglyceride (mmol/l) 1.46 (0.61) 1.50 (0.75) 0.81 1.79 (0.72) 1.62 (0.55) 0.21 0.30
HbA1c 6.5 (1.1) 6.8 (1.8) 0.40 6.1 (0.8) 6.0 (0.7) 0.17 0.24
Values are means (SD); n¼19.
There are no statistical differences between groups or with treatment in these measures.
BMI, body mass index; HbA1c, haemoglobin A1c; VO2peak, aerobic capacity.
Gut 2011;60:1278e1283. doi:10.1136/gut.2011.242073 1279
Hepatologyvoxel, SENSE torso array). Blinded quantiﬁcation of the spectra
(water and CH2 resonances) was performed using the java-based
magnetic resonance user interface (jMRUI version 3.0).
23 24
Following manual ﬁrst and second order phase correction,
spectra were analysed using a non-linear least squares algorithm
(AMARES).
25 IHL was expressed as a percentage of liver volume,
corrected for proton density of water and lipid.
26
Subcutaneous and visceral fat content was performed by
acquiring images at the L4/L5 junction using a three-point
Dixon sequence (TR/TE/number of averages/ﬂip angle 50 ms/
3.45, 4.60, 5.75 ms/1/308, matrix 1603109, median ﬁeld of view
(FOV) 440 mm, range 400e480 mm to suit subject size with
70% phase FOV). The slice was acquired during a breath-hold
and with slice thickness of 10 mm.
27 28 Fat and water were
separated, and binary gating applied to produce a map of
structures containing more than 50% fat, identiﬁed as subcuta-
neous and visceral fat. Awatershed algorithm was used to divide
the binary image into distinct areas and allowed easy separation
of the subcutaneous and visceral fat. ImageJ
29 was used to
subtract the two areas to produce the area of visceral fat.
Glucose control
Following an 8 h overnight fast a cannula was inserted into
a forearm vein. A 75 g glucose load (Lucozade Original; Glaxo
SmithKline, Brentford, UK) was consumed within 5 min. Blood
samples were taken at times 0, 5, 10, 15, 20, 30, 40, 50, 60, 75, 90
and 120 min. Samples were analysed for whole blood glucose
(YSI 2300 Stat Plus-D; Yellow Springs Instruments, Yellow
Springs, Ohio, USA), plasma non-esteriﬁed fatty acid (NEFA)
(NEFA-HA; Wako Ltd, Osaka, Japan) and plasma insulin (Coat-
A-Count Insulin RIA kit; Diagnostic Products Corporation,
California, USA). The area under the curve for the resulting
glucose response proﬁle was calculated using the trapezoidal
rule
30 and insulin resistance determined using the homeostasis
model assessment insulin resistance (HOMAeIR).
31 NEFA
suppression was assessed during the frequently sampled oral
glucose tolerance test (fsOGTT) and the 0e30 min change used
as a measure of NEFA suppression.
32
Fasting samples were also analysed in a clinical pathology
accredited laboratory (Newcastle Upon Tyne Hospital NHS
Foundation Trust, Department of Clinical Biochemistry) for:
ALT, total cholesterol, triacylglycerols and haemoglobin A1c
(HbA1c). Serum samples were collected in silica clot activator
polymer gel containing vacutainers (BD Diagnostics, Plymouth,
UK)dtotal cholesterol, triacylglycerols and ALTwere measured
using a Roche Modular P and test kits (Roche Diagnostics Ltd,
Burgess Hill, UK), respectively. HbA1c was measured using
a TOSOH HLC-723G7 (Tosoh Corporation, Tokyo, Japan).
Lipid oxidation at rest and submaximal exercise
Resting substrate oxidation was determined by expired gas
analysis using a Hans Rudolf breathing mask while participants
lay supine for 30 min in a quiet room. The ﬁrst 15 min were an
acclimatisation period and the second 15 min were used to
determine resting substrate oxidation. Following a 5-min warm
up on the recumbent cycle ergometer at 25 W, resistance was
increased to 50% of the maximal oxygen uptake determined at
screening and maintained for 60 min. Expired air was collected
every 15 min. Respiratory quotient was calculated from oxygen
consumption/carbon dioxide elimination.
Study intervention
Resistance exercise was performed three times per week on non-
consecutive days for 8 weeks. The programme consisted of eight
exercises: biceps curl; calf raise; triceps press; chest press; seated
hamstrings curl; shoulder press; leg extension and lateral pull
down (Precor, Woodinville, USA). Each session lasted between
45 and 60 min and consisted of a 10 min warm-up at approxi-
mately 60% maximum heart rate on a cycle ergometer followed
by resistance exercise done as a circuit, ending with a repeat of
the warm-up described. The one repetition maximum was
measured
33 at baseline and following the intervention. Initially,
participants did two circuits using 50% of their one repetition
maximum, progressing to three circuits, using a minimum 70%
of their one repetition maximum by week 7. Participants were
encouraged to increase the resistance used each week when
possible. Biweekly supervised sessions were used to encourage
adherence and progression and to resolve any problems. Heart
rate was recorded during each session (Polar RS400; Polar Electro
Oy, Kempele, Finland) and was used alongside exercise logs to
assess adherence.
Statistics
Following tests for normal distribution, between-group differ-
ences were evaluated using an unpaired t-test and within-group
differences using a paired t-test (two way). Treatment group 3
time interactions were assessed using a two-way analysis of
variance. Analyses were performed using Minitab version 15
(Minitab Inc., State College, Pennsylvania, USA). Statistical
signiﬁcance was set at p<0.05. Data are mean6SD unless
otherwise stated.
RESULTS
No subjects withdrew during the trial and all subjects allocated
to the exercise group completed all 24 sessions of resistance
exercise training. Two subjects (controls) were excluded from
analysis (one individual lost >5% of his body weight during the
8-week period and one had a change in his diabetes medica-
tion). Nineteen subjects (eight control; 11 exercise) completed
the study. The groups were well matched for weight, body
mass index and waist/hip circumference (table 1). The exercise
group were younger (52613.3; range 33e72 years) compared
with the control group (6267.4; range 51e71 years; p¼0.05).
There was no correlation between age and change in IHL
(p>0.05).
Anthropometry and body composition
Body mass index remained constant in both groups during the
study (3264.9 to 3264.5 vs 3264.8 to 3264.2 kg.m
2 in exercise
and control). There were no signiﬁcant changes in weight, waist
or hip circumference, waist to hip ratio, body composition,
visceral or subcutaneous fat in either group (see tables 1 and 2).
Intrahepatic lipid
Resistance exercise elicited a 13% relative reduction in IHL with
no change in the control (p<0.01; table 2, ﬁgure 1A). There was
a signiﬁcant time by treatment interaction for resistance exercise
(p<0.05; table 2, ﬁgure 1A) although the signiﬁcant fall in IHL
did not achieve a signiﬁcant difference between the two groups
at the end of the intervention. However, three of the partici-
pants in the exercise group moved from having clinically
signiﬁcant NAFLD to being within normal limits (<5% IHL).
No control subject moved into the normal liver fat range. The
change in IHL with both groups combined was weakly associ-
ated with the change in the number of steps walked per day
(R
2¼0.28, p<0.05), but not with active energy expenditure
(R
2¼0.06, p>0.05).
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HepatologyBlood lipids and liver enzymes
There were no signiﬁcant changes in blood lipids or ALT in either
group (table 1).
Glucose control
The exercise group demonstrated improved glucose control after
8 weeks as indicated by a decrease in glucose area under the
curve during the fsOGTTcompared with control (p<0.01; ﬁgure
1B; table 2). The exercise group showed a signiﬁcant improve-
ment in insulin sensitivity after 8 weeks, as demonstrated by
a decrease in HOMAeIR (5.965.9 to 4.664.6 vs 4.762.1 to
5.162.5; p<0.05; table 2), although time by treatment interac-
tion for resistance exercise and insulin resistance just missed
statistical signiﬁcance (p¼0.055). Fasting insulin levels remained
relatively unchanged in both groups (table 2). Fasting glucose
levels were reduced in the exercise group after the intervention
compared with the control but this was not statistically
signiﬁcant (6.062.1 to 5.260.9 vs 5.962.3 to 6.463.3 mmol/l;
p¼.086). Time by treatment interaction for resistance exercise
and change in fasting glucose was just outside statistical
signiﬁcance (p¼0.06). HbA1c remained relatively unchanged in
both groups (table 1).
NEFA suppression
Fasting plasma NEFA remained unchanged by the intervention.
Similarly, the extent of NEFA suppression during the fsOGTT
remained constant in both groups (table 2).
Fat oxidation
Resistance exercise brought about an increase in fat oxidation
during the submaximal exercise test (respiratory quotient
0.9360.02 to 0.9060.01 vs 0.9060.02 to 0.8960.02, p<0.05;
p<0.05 time by treatment interaction; table 2; ﬁgure 1C). Resting
fat oxidation remained constant in both groups (table 2).
Physical activity
There was a wide range of habitual daily activity (number of
steps taken daily measured by Sensewear) in both groups at
baseline (range 5046e12479 exercise, mean 8692; range
2781e9159 control, mean 5682). The total number of steps
taken on a daily basis was signiﬁcantly higher in the exercise
group post-intervention when compared with the controls
(984863338 vs 588363073; p¼0.028).
DISCUSSION
This is the ﬁrst study to examine the effects of resistance exer-
cise on IHL and its mediators in adults with NAFLD. An 8-week
resistance exercise programme brought about an approximately
13% reduction in liver fat. This was accompanied by an
approximately 12% increase in insulin sensitivity, and increased
fat oxidation during submaximal exercise in the absence of any
change in body weight.
Although lifestyle modiﬁcation combining dietary change and
exercise produces a robust reduction in IHL,
1 the data on exercise
alone is less deﬁnitive. We demonstrated that resistance exercise
without weight change is effective in reducing IHL in people
with NAFLD. Resistance exercise provides an alternative to
aerobic exercise; it improves muscular strength, muscle mass and
metabolic control, safely and effectively, in vulnerable popula-
tions independent of weight loss.
16 It places less of a demand on
the cardiorespiratory system and may therefore be accessible to
more patients.
17 All participants completed the 8-week
programme, showing good adherence and tolerance.
To date, only two studies have reported the effect of exercise
alone on liver health in adults with NAFLD, both having used
aerobic exercise, but only one reported a direct measure of IHL. A
4-week aerobic exercise intervention showed a similar absolute
reduction in IHL (
1H-MRS) as seen during the present study.
The aerobic exercise brought about a reduction in IHL from 8.6%
to 6.8%.
14 A 12-week intervention reported a 47% (47 U/l) and
48% (30 U/l) reduction in ALTand AST, respectively.
15 However,
these biomarkers can be elevated in the absence of excess liver fat
and within the normal range in the presence of elevated liver fat,
making them poor indicators for IHL.
34e36 Interestingly, the
present study is the ﬁrst to monitor habitual physical activity
alongside exercise therapy. These data suggest that changes in
physical activity habits and the brief aerobic warm up accom-
panying resistance exercise contributed to the change in IHL
only to a small extent. Although the changes in IHL following
exercise therapy are signiﬁcant, the absolute change (w2% IHL)
Table 2 Intrahepatic lipid concentration, subcutaneous and visceral adipose tissue, body composition, glucose control, insulin sensitivity, NEFA
suppression index and substrate oxidation during submaximal exercise
Control Exercise Time 3 treatment
interaction (p value) Baseline Post-treatment p Value Baseline Post-treatment p Value
Intrahepatic lipid (%) 11.2 (8.4) 11.5 (7.4) 0.80 14.0 (9.1) 12.2 (9.0) 0.01* 0.05y
Visceral adipose tissue (cm
2) 2558 (715) 2445 (644) 0.31 2098 (809) 2165 (816) 0.26 0.15
Subcutaneous adipose tissue (cm
2) 3512 (970) 3574 (936) 0.30 3275 (1165) 3221 (1180) 0.46 0.21
Fat mass (% body mass) 41 (6) 41 (7) 0.88 37 (8) 36 (8) 0.12 0.38
Fasting glucose (mmol/l) 5.9 (2.3) 6.4 (3.3) 0.33 6.0 (2.1) 5.2 (0.9) 0.08 0.06
Fasting insulin (pmol/l) 18.14 (4.52) 18.97 (9.82) 0.18 20.55 (13.68) 18.64 (13.25) 0.18 0.33
Fasting NEFA (mmol/l) 0.48 (0.13) 0.50 (0.17) 0.62 0.44 (0.19) 0.43 (0.13) 0.77 0.56
HOMAeIR 4.7 (2.1) 5.1 (2.5) 0.57 5.9 (5.9) 4.6 (4.6) 0.05z 0.06
fsOGTT, AUC 839 (299) 940 (421) 0.15 885 (269) 777 (184) 0.01* 0.01x
NEFA-S (0e30 min of fsOGTT) 0.07 (0.10)  0.02 (0.10) 0.15 0.00 (0.10) 0.00 (0.14) 0.99 0.25
Resting RQ 0.86 (0.09) 0.86 (0.06) 0.76 0.86 (0.05) 0.86 (0.06) 0.92 0.76
Submaximal exercise RQ 0.90 (0.02) 0.89 (0.02) 0.08 0.93 (0.02) 0.91 (0.01) 0.02z 0.05
Values are means (SD); n¼19.
*Signiﬁcant difference baseline versus post-treatment (p<0.01).
ySigniﬁcant difference treatment 3 time interaction (p<0.05).
zSigniﬁcant difference baseline versus post-treatment (p<0.05).
xSigniﬁcant difference treatment 3 time interaction (p<0.01).
AUC, area under the curve; fsOGTT, frequently sampled oral glucose tolerance test; HOMAeIR, homeostasis model of insulin resistance; NEFA-S, non-esteriﬁed fatty acid suppression index;
RQ, respiratory quotient.
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Hepatologywas modest compared with the approximately 10% reduction
reported after an 8 kg weight loss from caloric restriction.
37
Therefore, the clinical value of exercise in NAFLD appears likely
to be as an adjunct to caloric restriction.
Our observed improvement in glucose control is consistent
with ﬁndings in populations with impaired glucose control or
type 2 diabetes mellitus.
38 39 The aerobic exercise studies in
NAFLD have either reported no change
14 or not reported
measures of glucose control.
15
We observed a pure exercise effect on IHL, which did not
involve any change in visceral fat in the patients. There is
increasing evidence that the two depots are not mechanistically
linked but both tend to reﬂect adiposity.
3 Recent ﬁndings from
the Framingham Heart Study,
40 and a much smaller cohort,
41
show IHL to be associated with dyslipidaemia and dysglycaemia
independently of visceral fat. Our observation of decreased IHL
in the absence of any observable change in visceral or subcuta-
neous fat provides further information on the separate regula-
tion of IHL and visceral fat.
The mechanisms underlying the change in IHL following
exercise are likely to reﬂect changes in energy balance, circula-
tory lipids and insulin sensitivity. Insulin sensitivity plays
a signiﬁcant role in IHL homeostasis. High levels of circulatory
insulin upregulate SREBP-1c and ChREBP expression in the
liver,
42 43 stimulating de novo lipogenesis and increasing IHL. In
healthy normoglycaemic humans, hepatic de novo lipogenesis
contributes approximately 5% and 18e23% of IHL in the fasted
and postprandial states, respectively.
44 Whereas de novo lipo-
genesis is constantly elevated in those with NAFLD contributing
approximately 26% of IHL irrespective of feeding state,
45
elevated circulating triacylglycerols exacerbate this problem by
impeding insulin-stimulated glucose uptake.
46 This creates
a vicious cycle in which elevated IHL levels impede hepatic
insulin action, causing increased portal insulin levels and further
increasing IHL.
47
Our ﬁndings suggest that the introduction of resistance
exercise breaks this cycle by improving glucose control and fat
oxidation. Our observations would support other reports that
resistance exercise increases whole-body glucose disposal
48 at
least partly due to increases in skeletal muscle GLUT4, glycogen
synthase expression and activity, insulin receptor and glycogen
storage.
49 Skeletal muscle in the resistance exercising individual
can thus act to sequester circulating fatty acids and glucose
safely, reducing the impact of insulin-stimulated de novo lipo-
genesis in the liver. Aerobic exercise has been shown to increase
intramyocellular triacylglycerol synthesis,
50 51 while decreasing
the accumulation of fatty acid metabolites and suppressing the
proinﬂammatory state associated with insulin resistance.
52 It
remains to be determined whether exercise has any direct tran-
scriptional effects on the liver. Furthermore, as patients with
ﬁbrosis were excluded, the beneﬁts of resistance exercise upon the
progression of liver disease versus metabolic control cannot be
disentangled. It is also important to highlight that IHL is part of
the early adaptive response to stress rather than a ﬁrst hit in
disease progression. As such, IHL represents a biomarker of NEFA
ﬂux, oxidative, endoplasmic reticulum (ER) and cytokine-medi-
ated stress that results in steatosis and progressive liver damage.
53
In conclusion, well-tolerated resistance exercise reduced IHL,
increased insulin sensitivity, and improved metabolic ﬂexi-
bility in NAFLD independent of weight loss. The absolute
effect of resistance exercise studied in isolation was modest
but similar to that of aerobic exercise. The beneﬁts of resis-
tance exercise combined with caloric restriction in the clinical
management of NAFLD will depend upon long-term mainte-
nance and sustainability of exercisedthis now needs to be
investigated.
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